Newsroom
Sorted by: Latest
-
Riassunto: I dati dello studio clinico pivotale di EP0031 (A400), un inibitore selettivo di nuova generazione della chinasi RET (Selective RET Inhibitor - SRI), nel NSCLC metastatico positivo alla fusione di RET, verranno presentati all'ASCO 2026
LONDRA--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una società globale specializzata nello sviluppo di farmaci oncologici con una pipeline di programmi innovativi, ha annunciato oggi che il suo partner, Kelun-Biotech, sta presentando dati dallo studio clinico pivotale per EP0031/A400, per il potenziale trattamento del carcinoma polmonare non a piccole cellule (NSCLC) positivo alla fusione di RET, al Meeting annuale 2026 della American Society of Clinical Oncology (ASCO), che si terrà a Chic...
-
Resumen: Se presentarán en ASCO 2026 datos del estudio fundamental para EP0031 (A400), un inhibidor de RET selectivo (SRI) de próxima generación en NSCLC avanzado positivo para RET
LONDRES--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), una empresa de desarrollo de fármacos oncológicos global con una cartera de programas innovadores, anunció hoy que su socio, Kelun-Biotech, está presentando datos del estudio fundamental de EP0031/A400 para el potencial tratamiento de cáncer de pulmón de células no pequeñas (NSCLC) avanzado positivo para RET, en la reunión anual de la American Society of Clinical Oncology (ASCO) 2026, que se llevará a cabo en Chicago del 29 de mayo al 2 de...
-
Virta Health Notice of Data Event
DENVER--(BUSINESS WIRE)--Virta Health Corp. and Virta Medical PC (hereinafter, collectively “Virta Health”) is providing this substitute notice as a result of a security incident to provide individuals with information and to share resources available for those who wish to further safeguard their personal information. The privacy and protection of information is a top priority for Virta Health. On March 24, 2026, Virta Health identified unauthorized activity limited to a data repository that is...
-
-
AOA Statement on HHS Dismissal of USPSTF Vice Chairs
CHICAGO--(BUSINESS WIRE)--Access to evidence-based preventive services is central to delivering whole-person care and supporting long-term patient wellbeing. Representing more than 207,000 osteopathic physicians (DOs) and medical students in the U.S., we are deeply concerned by the abrupt dismissal of the United States Preventive Services Task Force (USPSTF) Vice Chairs and political interference in the USPSTF process. The USPSTF plays a critical role in healthcare coverage and access to servic...
-
Super Micro Computer 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against Super Micro Computer, Inc. - SMCI
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in securities class action lawsuits against Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI), if they purchased or otherwise acquired the Company’s securities between February 2, 2024 and March 19, 2026, inclusive (the “Cl...
-
Scotts Miracle-Gro Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Scotts Miracle-Gro Company - SMG
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into The Scotts Miracle-Gro Company (NYSE: SMG) (“Scotts” or the “Company”). On August 2, 2023, the Company disclosed disappointing financial results including a decline in quarterly sales for fiscal third quarter of 6%, a decline in gross margin by 420 basis points, as well a...
-
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”)....
-
Future Health Challenge 于世界卫生大会期间颁发 30 万美元奖金,表彰早期检测与群体健康感知工具创新成果
日内瓦--(BUSINESS WIRE)--(美国商业资讯)-- 在第 79 届世界卫生大会期间,三支专注于早期检测与实时群体健康监测解决方案的国际团队共获得 30 万美元奖金。获奖方案聚焦早期健康风险识别、持续性群体健康洞察以及更及时的决策支持等关键领域,体现出全球卫生体系正由“疾病后期治疗”加速向“早期干预与主动预防”转变。 本届“Future Health Challenge 2026:通过群体健康感知构建前瞻性卫生体系”由 “Future Health——阿布扎比发起的全球倡议” 联合 MIT Solve 共同举办,共吸引来自 68 个国家的 393 份参赛方案,最终遴选出获奖团队。 全球卫生体系正面临医疗支出不断上升与诊断延误长期存在的双重压力,许多疾病至今仍需待症状明显恶化后方能被确诊。与此同时,预防性医疗服务的可及性依然不均衡,医疗资源不足地区的社区在早期筛查、及时治疗以及获取可靠健康信息方面,往往面临更严峻的挑战。Future Health Challenge 因此聚焦于能够更早识别健康风险、持续监测群体健康数据,并协助卫生主管机构更迅速作出决策的创新解决方案。 五支入...
-
Future Health Challenge、世界保健総会の会期中に、早期検知および集団レベルの健康センシングツールに30万米ドルを授与
ジュネーブ--(BUSINESS WIRE)--(ビジネスワイヤ) -- 早期検知および集団レベルの健康状態をリアルタイムでモニタリングするソリューションを開発する世界各国の3チームが、第79回世界保健総会の会期中に、総額30万米ドルを獲得しました。受賞ソリューションは、早期検知、集団レベルの健康動向の継続的な把握、よりタイムリーな意思決定に関する重要課題に対応するものであり、保健医療システムが、病状が進行してからの治療から、より早期の介入へと移行しつつあることを示しています。 68か国から寄せられた393件の応募の中から選出された受賞チームは、Future Health – A Global Initiative by Abu DhabiがMIT Solveと連携して実施した、初開催の「Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing」において表彰されました。 世界の保健医療システムは、医療費の増加と診断の慢性的な遅れという課題に直面しており、多...